Print this page    •   Back to Web version of article

National Minority AIDS Council

March 15, 1996
Action Alert

Protease Inhibitor Crixivan (Indinavir Sulfate)
Approved by FDA

The U.S. Food and Drug Administration (FDA) approved a new protease inhibitor Crixivan, the first anti-HIV drug developed by Merck's AIDS research program.

Crixivan disables the protease enzyme that enables HIV to replicate. Crixivan can be taken alone or in combination with other anti-HIV drugs such as AZT or 3TC.

Is Crixivan Effective? Yes!

How much will Crixivan Cost?

How to get Crixivan:

Why Time is of the Essence:


The National Minority AIDS Council (NMAC) is a national membership organization that represents over 600 community-based organizations. These frontlines organizations provide outreach, care, education, housing and support services to thousands of men and women in communities of color. NMAC provides visibility, leadership, educational messages, comprehensive technical assistance and most important a powerful national voice to these frontline AIDS workers.


For more information contact
Moisés Agosto or Richard Ehara
National Minority AIDS Council
1931 13th Street, NW
Washington, DC 20009
Research and Treatment Advocacy Department
Tel: 202-483-6622
Fax: 202-483-1135




This article was provided by National Minority AIDS Council. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art6281.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.